0
0
MUMBAI, India — In a move set to transform the logistics of oncology care, Roche Pharma India announced on Thursday the launch of the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer. The new formulation of atezolizumab, marketed as Tecentriq SC, can be administered in approximately seven minutes—a stark contrast to the standard intravenous (IV) infusions that typically require 30 to 60 minutes of chair time and several hours of total hospital stay.
The approval by the Central Drugs Standard Control Organisation (CDSCO) covers eligible adult patients with certain types of non-small cell lung cancer (NSCLC), both in early-stage adjuvant and advanced metastatic settings. While the core medicine remains the same, this “jiffy” delivery system aims to address the significant physical and emotional toll that long treatment sessions take on patients and the overstretched healthcare infrastructure in India.
Faster Delivery, Same Efficacy
The innovation behind Tecentriq SC lies in the use of Enhanze® drug delivery technology, which utilizes a recombinant human enzyme called hyaluronidase. This enzyme temporarily breaks down hyaluronan—a natural sugar chain under the skin—allowing the 1,875 mg dose of atezolizumab to be absorbed rapidly into the bloodstream.
Traditional immunotherapy involves a slow drip into a vein, often requiring a dedicated infusion nurse and a specialized port or cannula. The new subcutaneous version is a single injection, usually given in the thigh.
“By reducing treatment administration time to approximately seven minutes, this innovation has the potential to dramatically improve the cancer treatment experience,” said Sivabalan Sivanesan, Chief Medical Officer of Roche Pharma India, in a press statement. Roche estimates that for every patient treated via conventional IV, up to five could be treated using the subcutaneous method within the same timeframe.
The Evidence: IMscin001 and IMscin002
The clinical foundation for this launch rests on the IMscin001 and IMscin002 global trials. In these studies, researchers compared the subcutaneous formulation to the original IV version in patients with advanced NSCLC.
-
Pharmacokinetic Equivalence: The IMscin001 trial, involving 371 patients, showed that the levels of the drug in the blood (pharmacokinetics) were comparable between the two delivery methods.
-
Survival and Response: Final data published earlier this year indicated a median overall survival of 10.9 months for the SC group compared to 10.1 months for the IV group—a statistically insignificant difference that confirms the new delivery method does not compromise the drug’s efficacy.
-
Patient Preference: The IMscin002 crossover study revealed a striking trend: approximately 71% of patients preferred the subcutaneous injection. Cited reasons included reduced emotional distress, greater physical comfort, and significantly less time spent in the clinic.
Public Health Context: The Burden in India
Lung cancer is a major public health challenge in India, with nearly 80,000 new cases diagnosed annually. According to the World Health Organization (WHO), it remains the leading cause of cancer-related deaths globally, claiming 1.8 million lives in 2022.
In India, the challenge is compounded by late-stage diagnoses and a shortage of oncology beds in major government and private centers. Most patients travel long distances with caregivers, losing entire days of work and income for a single treatment session.
“The shift toward shorter administration times isn’t just about convenience; it’s about capacity,” notes an independent oncology consultant not involved with the Roche launch. “If we can move patients through the ‘infusion chair’ faster, we can clear the backlog of people waiting for life-saving care.”
Cost and Accessibility: The Reality Check
Despite the clinical and logistical benefits, the “seven-minute” treatment comes with a high price tag. The Maximum Retail Price (MRP) for Tecentriq SC is approximately ₹3.7 lakh to ₹4 lakh per vial. Since most patients require around six cycles—and some many more depending on disease progression—the total cost can quickly exceed ₹20 lakh.
While Roche has indicated it offers Patient Access Programs (PAP) to provide financial support or free vials to eligible patients, the treatment remains out of reach for a vast majority of the Indian population without comprehensive insurance or government backing.
Furthermore, medical experts caution that the “faster” delivery does not mean “easier” monitoring. Patients still require thorough evaluation for immune-related adverse events (irAEs), such as pneumonitis (lung inflammation) or colitis, which can occur regardless of how the drug is administered.
Limitations and Patient Outlook
While the SC formulation reduces infusion-related reactions often seen with IV drips, it carries a higher risk of local injection-site reactions, such as redness or stinging at the site of the needle. Additionally, the subcutaneous version is currently approved only for adult indications, leaving pediatric applications (though rare in NSCLC) out of the current scope.
For the general public, the launch serves as a reminder of the evolving landscape of “patient-centric” care. However, doctors emphasize that these innovations are most effective when cancer is caught early. Symptoms like a persistent cough, shortness of breath, or coughing up blood should be evaluated immediately by a specialist.
As India integrates this new technology, the focus will likely shift to real-world data to see if the theoretical “time-saving” benefits translate into better healthcare access for the thousands currently waiting in oncology queues across the country.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
https://health.economictimes.indiatimes.com/news/industry/7-minute-lung-cancer-immunotherapy-launched-in-india-slashing-treatment-time-by-80/131089780?utm_source=top_story&utm_medium=homepage
